MARKET

MRTX

MRTX

Mirati
NASDAQ

Real-time Quotes | Nasdaq Last Sale

161.03
+1.54
+0.97%
After Hours: 161.03 0 0.00% 16:00 09/24 EDT
OPEN
158.17
PREV CLOSE
159.49
HIGH
162.39
LOW
155.51
VOLUME
375.34K
TURNOVER
--
52 WEEK HIGH
171.48
52 WEEK LOW
66.01
MARKET CAP
7.17B
P/E (TTM)
-22.5868
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
High Hopes for Amgen and Gilead at Europes Biggest Cancer Research Conference
Europe’s biggest conference for cancer researchers will be a virtual affair this weekend, but it is still expected to be a big deal for companies like Amgen and for Immunomedics, which just agreed to a $21 billion acquisition by Gilead Sciences. undefined
Barrons.com · 6d ago
Qorvo, Inc. -- Moody's announces completion of a periodic review of ratings of Qorvo, Inc.
Moody's · 6d ago
Mirati Therapeutics Highlights Presentation Of Phase 2 Data On Sitravatinib In Combo With Nivolumab In Urothelial Cancer At European Society For Medical Oncology Sept. 19-21
Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO®) in
Benzinga · 6d ago
Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual Congress
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO®) in patients with advanced or metastatic urothelial carcinoma. Sitravatinib is an investigational
PR Newswire · 6d ago
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 6d ago
Mirati Therapeutics teams up with Boehringer Ingelheim in cancer study
Germany-based Boehringer Ingelheim will collaborate with Mirati Therapeutics (MRTX) on a clinical trial evaluating the combination of BI 1701963, a SOS1::pan-KRAS inhibitor blocking KRAS independent of mutation type, and the latter's MRTX849, a KRAS G12C selective inhibitor,
Seekingalpha · 09/17 12:53
Boehringer Ingelheim And Mirati Therapeutics Announce Clinical Collaboration To Study BI 1701963, A SOS1::pan-KRAS Inhibitor In Combination With MRTX849, A KRAS G12C Selective Inhibitor
INGELHEIM, Germany and SAN DIEGO, Sept. 17, 2020 /PRNewswire/ --Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ:MRTX) today announced a clinical collaboration to evaluate the
Benzinga · 09/17 12:06
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)
Benzinga · 09/17 11:59
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRTX. Analyze the recent business situations of Mirati through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRTX stock price target is 152.57 with a high estimate of 200.00 and a low estimate of 85.00.
EPS
Institutional Holdings
Institutions: 277
Institutional Holdings: 58.27M
% Owned: 130.83%
Shares Outstanding: 44.54M
TypeInstitutionsShares
Increased
84
2.57M
New
63
272.12K
Decreased
49
2.87M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Director
Faheem Hasnain
Chairman/Director
faheem Hasnain
President/Chief Executive Officer/Director
Charles Baum
Chief Operating Officer/Executive Vice President
Daniel Faga
Executive Vice President/Chief Scientific Officer
James Christensen
Executive Vice President
Benjamin Hickey
Senior Vice President/Chief Accounting Officer
Vickie Reed
Other
Joseph Leveque
Independent Director
Bruce Carter
Vice President/Director of Human Resources
Jenny Gizzi
Independent Director
Julie Cherrington
Independent Director
Aaron Davis
Independent Director
Henry Fuchs
Independent Director
Michael Grey
Independent Director
Craig Johnson
Independent Director
Maya Martinez-Davis
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MRTX
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company develops product candidates to address the genetic and immunological promoters of cancer. Its clinical programs consist of two product candidates: MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor, and Sitravatinib, a multi-kinase inhibitor. Its KRAS inhibitor program is focused on the discovery and development of small molecule compounds that target KRAS G12C and G12D. MRTX849 is designed to inhibit KRAS G12C mutations which are present in non-small cell lung cancer (NSCLC) adenocarcinoma patients, colorectal cancer (CRC) patients, pancreatic cancer patients, as well as several other difficult-to-treat cancers. Sitravatinib is a spectrum-selective kinase inhibitor designed to inhibit receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Mirati Therapeutics Inc stock information, including NASDAQ:MRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRTX stock methods without spending real money on the virtual paper trading platform.